Reckitt Benckiser’s Mead Johnson unit and Abbott Laboratories have been ordered to face a new trial in the US over ...

Abbott Laboratories ABT has witnessed strong momentum in the past year. Shares of the company have risen 12.7% compared with the 9% growth of the industry during the same time frame. The S&P 500 ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

In the last year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a substantial stake in the company which may ...

Missouri 22nd Judicial Circuit Court Judge Michael Noble granted the plaintiff's motion for a new trial on Thursday, citing ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...

We recently published a list of Friday’s 10 Worst Performing Stocks. In this article, we are going to take a look at where ...

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in their ...

Back in October, a jury found North Chicago-based Abbott and Reckitt’s formula subsidiary Mead Johnson not responsible for a ...

Shares of Abbott Laboratories ABT slid 3.42% to $132.66 Tuesday, on what proved to be an all-around rough trading session for ...